Investigating antiviral treatment in COVID-19
When COVID-19 entered the world stage in late 2019, it was clear that this virus could cause severe lung illness. Many people were becoming so breathless they required hospitalisation, supplemental oxygen and ventilation. Human lungs were not coping as they should with this virus.
Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries.
SG016 Trial
Phase 2 double-blind, placebo-controlled trial of inhaled IFN-β , SNG001, in hospitalised COVID-19 patients
Access the results of SG016 in the Lancet Respiratory Medicine.
SG018 SPRINTER Trial
Phase 3 double-blind, placebo-controlled, trial of inhaled IFN-β, SNG001, in hospitalised COVID-19 patients
Access the results of SG018 in the European Respiratory Journal Open Research (ERJOR).
The ACTIV-2 Trial
SNG001 investigated independently as part of the US National Institute of Health’s ACTIV programme to accelerate the development of the most promising COVID-19 treatments
SNG001 was investigated independently as part of the US National Institute of Health’s ACTIV programme to accelerate the development of the most promising COVID-19 treatments. The ACTIV-2 study (ClinicalTrials.gov Identifier: NCT04518410), was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended in October 2021 that SNG001 advance from Phase 2 into Phase 3 in the ACTIV-2 trial. However, in March 2022 as the Company and the ACTIV-2 team were preparing to initiate recruitment for Phase 3, the NIAID halted all patient recruitment in ACTIV-2 and discontinued all arms of the trial, including the one to evaluate SNG001, due to the significant shift in the nature of the pandemic which would necessitate a substantial modification of the study design which was not feasible in a multiple treatment-arm platform trial of this size.
Read the full results from the study in The Lancet.